We are live on ! Find out more
EAM

EFG Asset Management Portfolio holdings

AUM $773M
1-Year Est. Return 40.1%
This Fund
S&P 500
This Quarter Est. Return
-3.52%
1 Year Est. Return
+40.1%
3 Year Est. Return
+211.13%
5 Year Est. Return
10 Year Est. Return
AUM
$421M
AUM Growth
-$44.9M
Cap. Flow
-$19.8M
Cap. Flow %
-4.71%
Top 10 Hldgs %
16.37%
Holding
207
New
16
Increased
62
Reduced
115
Closed
14

Top Buys

Rank Stock Value
1
ZS icon
Zscaler
ZS
+$2.72M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.86M
3
ROIV icon
Roivant Sciences
ROIV
+$1.84M
4
CERT icon
Certara
CERT
+$1.81M
5
GEHC icon
GE HealthCare
GEHC
+$1.69M

Sector Composition

Rank Sector Weight
1 Healthcare 37.85%
2 Technology 22.51%
3 Industrials 10.95%
4 Consumer Discretionary 10.86%
5 Communication Services 7.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DKS icon
51
Dick's Sporting Goods
DKS
$17.5B
$2.83M 0.67%
26,038
-12,610
-33% -$1.6M
ZS icon
52
Zscaler
ZS
$24B
$2.82M 0.67%
+18,131
New +$2.72M
ZG icon
53
Zillow
ZG
$7.74B
$2.82M 0.67%
62,851
-517
-0.8% -$26K
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.59B
$2.75M 0.65%
22,712
-1,582
-7% -$179K
CRL icon
55
Charles River Laboratories
CRL
$11.1B
$2.75M 0.65%
14,028
+770
+6% +$158K
PANW icon
56
Palo Alto Networks
PANW
$265B
$2.69M 0.64%
22,984
-12,380
-35% -$1.47M
EXAS
57
DELISTED
Exact Sciences
EXAS
$2.69M 0.64%
39,461
+1,372
+4% +$116K
RGEN icon
58
Repligen
RGEN
$7.89B
$2.61M 0.62%
16,452
+4,890
+42% +$799K
PODD icon
59
Insulet
PODD
$11.4B
$2.46M 0.58%
15,424
-166
-1% -$37.2K
COST icon
60
Costco
COST
$421B
$2.43M 0.58%
4,308
+854
+25% +$471K
PRGO icon
61
Perrigo
PRGO
$1.4B
$2.41M 0.57%
75,530
-5,262
-7% -$185K
CPRT icon
62
Copart
CPRT
$26.8B
$2.22M 0.53%
51,450
+19,002
+59% +$845K
GKOS icon
63
Glaukos
GKOS
$9.86B
$2.15M 0.51%
28,648
-2,736
-9% -$204K
GTLS
64
DELISTED
Chart Industries
GTLS
$2.14M 0.51%
12,644
-4,076
-24% -$685K
HD icon
65
Home Depot
HD
$329B
$2.11M 0.5%
6,979
+2,057
+42% +$662K
RARE icon
66
Ultragenyx Pharmaceutical
RARE
$2.44B
$2.07M 0.49%
57,921
+4,250
+8% +$168K
ONTO icon
67
Onto Innovation
ONTO
$12.8B
$2.05M 0.49%
16,112
-6,509
-29% -$774K
AXNX
68
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.97M 0.47%
35,154
+5,719
+19% +$322K
ROIV icon
69
Roivant Sciences
ROIV
$24.5B
$1.91M 0.45%
+163,024
New +$1.84M
QDEL icon
70
QuidelOrtho
QDEL
$1.09B
$1.9M 0.45%
26,060
+2,433
+10% +$194K
SPSC icon
71
SPS Commerce
SPSC
$2.67B
$1.9M 0.45%
11,121
+291
+3% +$51.7K
AZEK
72
DELISTED
The AZEK Co
AZEK
$1.89M 0.45%
63,396
+1,139
+2% +$35.8K
KRYS icon
73
Krystal Biotech
KRYS
$10.3B
$1.88M 0.45%
16,234
-1,550
-9% -$189K
WING icon
74
Wingstop
WING
$3.62B
$1.88M 0.45%
10,426
-1,196
-10% -$207K
ONC
75
BeOne Medicines Ltd
ONC
$32.5B
$1.86M 0.44%
10,369
+925
+10% +$183K

Similar funds

EFG Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, EFG Asset Management held 207 positions worth $421M, down 9.6% from $466M the previous quarter. Its ten largest holdings account for 16% of the portfolio.

EFG Asset Management withdrew a net $19.8M in Q3 2023, closing 14 positions and reducing 115 holdings. Its most notable exit was CoStar Group, an estimated $4.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 38% a quarter earlier, followed by Technology and Industrials.

Against the trend, EFG Asset Management opened a new position in Zscaler worth $2.82M.

  • EFG Asset Management's largest Q3 2023 buy was Zscaler: 18,131 shares worth $2.82M.
  • EFG Asset Management added most to BioMarin Pharmaceuticals in Q3 2023, an estimated $1.86M increase.
  • EFG Asset Management's biggest Q3 2023 reduction was Blueprint Medicines, cutting an estimated $3.38M.
  • EFG Asset Management fully exited CoStar Group in Q3 2023, selling an estimated $4.92M.
  • EFG Asset Management's ten largest holdings make up 16% of its $421M portfolio in Q3 2023.
  • EFG Asset Management opened 16 new positions and closed 14 in Q3 2023.
  • EFG Asset Management's portfolio value fell 9.6% quarter-over-quarter to $421M.

Based on EFG Asset Management's 13F filing for Q3 2023, filed 2 Nov 2023.